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Summary
Previously undescribed prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages
in neurogenesis. One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes
enriched for neural stemcell markers display equally short survival. Poor prognosis subclasses exhibitmarkers either of pro-
liferation or of angiogenesis andmesenchyme. Upon recurrence, tumors frequently shift toward themesenchymal subclass.
Chromosomal locations of genes distinguishing tumor subclass parallel DNA copy number differences between subclasses.
Functional relevance of tumor subtype molecular signatures is suggested by the ability of cell line signatures to predict
neurosphere growth. A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch
signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively.Introduction
High-grade gliomas (HGGs), which include glioblastoma (GBM)
and anaplastic astrocytoma (AA), are themost common intrinsic
brain tumors in adults and are nearly uniformly fatal. While there
has been progress in understanding the molecular genetics of
these tumors (Kitange et al., 2003), the cell type(s) of origin are
still uncertain, and the molecular determinants of disease ag-
gressiveness are not well understood. A better understanding
of the cellular origin and molecular pathogenesis of these tu-
morsmay identify new targets for treatment of these neoplasms.
Until recently, HGGs were presumed to arise from glial cells
residingwithin the brain parenchyma. However, recent evidence
in human and animal studies suggests neural stem cells as an
alternate cellular origin of gliomas (Caussinus and Gonzalez,
2005; Singh et al., 2003; Zhu et al., 2005). Mouse modelsCANCER CELL 9, 157–173, MARCH 2006 ª2006 ELSEVIER INC. DOI 10demonstrate that astrocytes or neural stem/progenitor cells
can give rise to neoplasms that recapitulate the histopathologi-
cal hallmarks of human gliomas (Bachoo et al., 2002; Uhrbom
et al., 2002). Demonstrations that the adult human forebrain
contains an abundant source of neural stem cells (Sanai et al.,
2004) and that human GBMs contain tumorigenic neural stem-
like cells (Galli et al., 2004; Ignatova et al., 2002; Singh et al.,
2004) indicate that neural stem and/or progenitor cells are
a plausible origin for human gliomas and have given rise to spec-
ulation that more effective therapies will result from approaches
aimed at targeting the stem cell-like component of GBM (Berger
et al., 2004; Fomchenko and Holland, 2005; Ignatova et al.,
2002; Oliver and Wechsler-Reya, 2004). Importantly, however,
the contribution of stem-like cells to disease progression or ther-
apeutic response has not been established, nor is it clear what
proportion of tumor cells exhibit stem-like properties.S I G N I F I C A N C E
Recent evidence suggests that gliomas may arise from a cell type with neural stem cell-like properties. The current work demonstrates
that prognostic subtypes of glioma resemble key stages in neurogenesis and implicates signaling pathways that play critical roles in
regulation of forebrain neurogenesis in control of tumor aggressiveness. Longitudinal analysis of glioma cases reveals a frequent
pattern of disease progression into the mesenchymal phenotype, a state associated with robust angiogenesis. This work suggests
that molecular classification of glioblastoma may predict response to targeted therapies and suggests that greater understanding
of neurogenesis in the adult forebrain may yield novel therapeutic insights for glial malignancies..1016/j.ccr.2006.02.019 157
A R T I C L EFigure 1. Expression profiling reveals three major patterns of gene expression related to survival in HGG
A: Unsupervised clustering of 76 primary astrocytomas by expression of 108 genes positively or negatively correlated with survival (gene clusters labeled pos-
itive or negative) reveals three sample clusters (red lines).
B: PN, Prolif, and Mes tumor subsets are identified using 35 signature genes. Centroids from k-means clustering are depicted using Z score-normalized gene
expression values (scale from 21 to +1).158 CANCER CELL MARCH 2006
A R T I C L ESeveral studies have investigated molecular correlates of
prognosis and clinical subclasses in AA and GBM (also known
as grade III and IV astrocytoma, respectively). Tumor grade is
the most established and robust predictor of disease outcome
(Prados and Levin, 2000). Loss of chromosome (chr) 10q is a
more frequent occurrence in GBM than AA and has been asso-
ciated with short GBM survival (Balesaria et al., 1999; Schmidt
et al., 2002; Smith et al., 2001). While p53 mutation and EGFR
amplification reportedly define mutually exclusive GBM sub-
groups (von Deimling et al., 1995; Watanabe et al., 1996), a re-
cent study challenges the validity of this classification scheme
(Okada et al., 2003), and the prognostic value of either p53mu-
tation or alterations of the EGFR locus is not clear (Heimberger
et al., 2005; Ushio et al., 2003).
Microarray expression profiling of gliomas has identified mo-
lecular subtypes as well as genes associated with tumor grade,
progression, and patient survival (Godard et al., 2003; Rickman
et al., 2001; van den Boom et al., 2003). While GBM and AA con-
tinue to be defined by histological criteria, reports that expres-
sion profiles predict outcome better than histological class
(Freije et al., 2004; Nutt et al., 2003) provide support for the
hypothesis that neoplasms defined morphologically as AA and
GBM represent a mix of molecular genetic subtypes. Given
the possibility that molecularly distinct disease entities may ex-
hibit different clinical responses, a greater understanding of the
behavior of molecularly defined subsets of tumorsmay aid in the
development of more effective therapies.
Efforts to develop targeted therapies for glial malignancies
have been hampered by complexities arising from intratumoral
and intertumoral molecular heterogeneity. An additional chal-
lenge in the management of gliomas is the nearly universal pro-
pensity of these neoplasms to contain cells that survive surgery
and radiation therapy and form recurrent lesions that are resis-
tant to further treatment. Methods to classify tumors according
to key molecular events that regulate growth of their most
aggressive cellular component and to predict changes that ac-
company disease recurrence might greatly facilitate develop-
ment of targeted therapies. In the current study, we identify mo-
lecular subclasses of high-grade astrocytoma with prognostic
value, relate these tumor subtypes to activation of signaling
pathways, and identify changes in gene expression that com-
monly accompany recurrence. Parallels between the prognostic
tumor subclasses identified in this study and stages in the dif-
ferentiation of neural stem cells suggest that aggressiveness
of HGGs is regulated by processes similar to those that control
forebrain neurogenesis.
Results
Molecular signatures define prognostic subclasses
of high-grade astrocytoma
Seventy-six samples from newly diagnosed cases of WHO
grade III and IV astrocytomas from M.D. Anderson Cancer Cen-
ter (MDA) were profiled via DNA microarrays to identify geneCANCER CELL MARCH 2006expression patterns that classify tumors into prognostic groups
(Figures 1A–1C). All tumor cases analyzed are described in Ta-
ble S1 in the Supplemental Data available with this article online.
We first identified probe sets whose expression most strongly
correlated with survival (Spearman r of log-transformed expres-
sion intensity values versus survival times >0.45 or <20.45), fol-
lowed by two-way agglomerative clustering of the 108 resulting
probe sets and 76 samples. This analysis identified three dis-
crete groups of sample sets that differ markedly in their expres-
sion of the survival-related genes (Figure 1A).
In order to define markers for each of the three tumor sub-
classes, we identified probe sets most strongly overexpressed
by each tumor subgroup as compared to remaining subclasses
(see Table S3). Using the most robust markers for each of the
three tumor subsets, we derived a set of 35 genes, referred to
as signature genes, that can be used in either hierarchical clus-
tering (Figure 1B) or k-means clustering to assign tumors to sub-
class. The HGG subclasses defined by k-means clustering are
designated proneural (PN), proliferative (Prolif) and mesenchy-
mal (Mes) to recognize the dominant feature of the gene list
that characterizes each subclass. For each tumor subclass,
a centroid was calculated from the average expression values
of the 35 signature genes (Figure 1B). A centroid can be viewed
as the prototypical expression pattern for a tumor subtype, and
additional samples can be classified by similarity of signature
gene expression to these centroids. Kaplan-Meier plots for
cases in the MDA data set showed that median survival of the
PN subclass (174.5 weeks) wasmarkedly longer than either Pro-
lif (60.5) orMes subtypes (65.0 weeks; Figure 1C). Classification
of a published data set of HGG (Freije et al., 2004) by similarity to
centroids defined by the MDA data set revealed very similar dif-
ferences in survival between PN tumors and the other sub-
classes (Table S1; Figure S1).
To determine if this classification scheme has prognostic
value independent of tumor grade, we utilized an additional in-
dependent set of 31 cases treated at University of California
San Francisco (UCSF). These tumors, all WHO grade IV astrocy-
tomas with necrosis, were classified as PN, Prolif, or Mes by
similarity of signature gene expression to centroids defined by
theMDA data set (Table S6). Significant prognostic value of mo-
lecular classification was seen within this set of histologically
uniform HGGs (Figure 1D). In addition, application of a multivar-
iate Cox model to a combined data set containing a total of 115
grade III and grade IV astrocytomas fromMDA and UCSF (Table
S1) revealed that tumor subtype has significant prognostic value
(p < 0.02) that is independent of WHO tumor grade and/or the
presence of necrosis, a variable within GBMs that is reported
to correlate with survival (Barker et al., 1996).
We next compared expression of selected PN and Mes
markers by both microarray and quantitative real-time PCR
(qPCR). We chose delta-like ligand 3 (DLL3) and CHI3L1/
YKL-40 (YKL40) as PN and Mes markers, respectively, from
the signature gene list and brevican (BCAN) and CD44 from
the more extensive list of markers (Table S3) for these sameC and D: Kaplan-Meier plots showing survival of all MDA cases (C) or of UCSF grade IV cases with necrosis (D). p values from log-rank tests shown. Green, blue,
and red lines correspond to PN, Prolif, and Mes subclasses, respectively. Vertical ticks indicate censored survival observations.
E: Survival of PN HGG as a function of histological grade.
F and G: Strong expression of PN markers and strong expression of Mes markers are mutually exclusive. Each bar depicts mRNA determinations by microarray
(F) or TaqMan real-time PCR (G) of four marker genes in an individual sample. Genes include BCAN, DLL3, YKL40, and CD44 as indicated. Values displayed
represent Z scores for gene expression of individual samples relative to the entire sample set.
H: In situ hybridization of BCAN and YKL40 in tissue microarray cores of five glioma cases. Arrows indicate focal YKL40 expression in BCAN-positive cores.159
A R T I C L EFigure 2. Most HGGs are characterized by strong similarity to one of three patterns of signature gene expression, and subclass shifts upon disease progression
are toward the Mes phenotype
A–C: Three-dimensional graphical representation in which the position occupied by each point represents the similarity (Spearman r) between an individual
sample and each of three centroids defined by k-means clustering of the reference (MDA) sample set.A:Nearly all grade III tumors of both astrocytic (blue) or
oligodendroglial (green) morphology are most similar to the PN centroid, while the population of grade IV tumors (red) is more evenly divided by similarity to160 CANCER CELL MARCH 2006
A R T I C L Etwo subclasses, respectively. Most glioma samples displayed
expression values above the population mean for either both
PN markers or both Mes markers, but rarely for combinations
of PN and Mes markers (Figures 1F and 1G).
In situ hybridization on a set of independent tumor cases con-
firmed a mutually exclusive pattern of expression for BCAN and
YKL40 mRNAs (Figure 1H). Most specimens displayed strong
signal for either BCAN or YKL40, but not both markers. Some
specimens did, however, display focal expression of each of
the two markers in nonoverlapping cellular elements. Most typ-
ically, these were specimens with small foci of YKL40 expres-
sion in specimens containing broad BCAN-positive regions. In
such cases, YKL40 was frequently expressed in tumor cells as-
sociated with blood vessels.
PN, Prolif, and Mes signatures define tumor
subpopulations that differ in tumor grade and patient age
Expanding our analysis to include a total of 256 HGGs (Table
S1), we observed that most tumors displayed a strong similarity
to one of the three centroids and a neutral or negative correlation
with the other two centroids. This finding is reflected by the ten-
dency of samples to cluster at the apices of a triangle in the
three-dimensional plot displayed in Figure 2A. While some sam-
ples showed intermediate similarity to two centroids, very few
samples showed weak or neutral similarities to all three cen-
troids. Thus, most HGGs tend to reside in one of three discrete
phenotypic states, and more rarely exist in a condition interme-
diate between two states.
These HGG subclasses displayed a strong association with
histological tumor grade (p < 1 3 10214, Fisher’s exact or chi-
square test). Nearly all WHO grade III tumor specimens exam-
ined (65/73 or 89%) were classified as PN regardless of whether
they exhibited oligodendroglial or astrocytic morphology. In
contrast, a significant proportion of WHO grade IV lesions
(GBM) were classified into each of the three molecular cate-
gories. Of 183 GBM samples examined, 31% were PN, 20%
were Prolif, and 49% were Mes.
Of the 115 HGG cases fully annotated for histological fea-
tures, we found that while PN HGGs contain a mixture of
WHO grade III tumors (AA) as well as WHO grade IV tumors
(GBM) with or without necrosis, Mes and Prolif HGGs are pre-
dominantly or exclusively WHO grade IV tumors with necrosis.
Of the WHO grade IV cases for which full histology was avail-
able, 36% (8/22) of PN subtype lacked necrosis, while only
7.5% (3/40) ofMes and 0% (0/29) ofProlif subtypes lack this fea-
ture. Among PN HGGs, however, WHO grade IV cases with or
without necrosis showed no difference in survival time (log
rank p > 0.80, Figure 1E).
Consistent with well-established correlations of both tumor
grade and survival time to patient age, we found that molecular
classification of tumors stratifies patients on the basis of age.
Among 185 newly diagnosed cases of HGG (n = 115 MDA and
UCSF; n = 70UCLA; Table S1),PN subclass caseswere youngerCANCER CELL MARCH 2006than those in either the Prolif or Mes subclass (p < 0.005, Stu-
dent’s t tests for both comparisons). Mean age 6 SEM for pa-
tients with tumors of PN, Prolif, and Mes subclass was 40.5 6
1.4 years, 49.0 6 2.5 years, and 50.7 6 1.3 years, respectively.
For WHO grade IV tumors in this sample set, Mes cases were
older than PN (p < 0.05, Student’s t test), while Prolif cases did
not differ in age from either of the other two classes.
PN, Prolif, andMes signatures characterize distinct sets
of normal tissues
To gain insights into the biological significance of the PN, Prolif,
and Mes tumor signatures, we examined expression of the 35
signature genes in several human tissue and cell types. This
analysis revealed that distinct sets of tissues resemble each of
glioma subclasses (Figure 2B; Table S4). Both fetal and adult
brain had a positive correlation with the PN centroid. Two neural
stem cell lines derived from fetal human brain also displayed
a PN phenotype under normal culture conditions. Tissues dis-
playing the Mes signature included bone, synovium, smooth
muscle, endothelial, and dendritic cells. In addition, a sample
of cultured human fetal astrocytes displayed a clear positive as-
sociation with the Mes centroid. Both hematopoietic stem cells
isolated from peripheral blood and the highly proliferative cell
line Jurkat had a strong association with the Prolif centroid. In-
terestingly, the two neural stem cell lines shifted signature sub-
class from the PN to theMes class in response to treatment and
withdrawal of the neurotrophic factor BDNF.
Upon recurrence, tumors tend to shift toward
the Mes phenotype
To determine if the molecular signatures that define HGG sub-
classes are a fixed feature of each tumor case or may change
after treatment and disease progression, we compared signa-
tures of 26 pairs of matched specimens that represent primary
and recurrent astrocytomas from the same patients. The mean
change in signature in all primary versus recurrent sample pairs
corresponded to a loss in similarity to the PN centroid of 0.186
0.06 (mean shift in Pearson r 6 SEM), a gain in similarity to the
Mes centroid of 0.20 6 0.09, and very little change in similarity
to the Prolif centroid (gain of 0.02 6 0.08). The differences in
shifts with respect to PN andMes centroids was statistically sig-
nificant (p < 0.005, Student’s t test). Eighteen of the 26 matched
pairs remained in the samemolecular subclass, while eight pairs
changed class upon recurrence (Figure 2C). Of these eight pairs,
all but one represent shifts into the Mes subclass.
Using a pairwise analysis, significance analysis of microarrays
(SAM) identified genes upregulated in the recurrent tumors that
switched into theMes subclass (Figure 2D). Upregulated genes
included YKL40, CD44, and STAT3, genes previously implicated
in GBM biology as well as vimentin (VIM), a classic marker of
mesenchymal tissues (Eibl et al., 1995; Rahaman et al., 2002;
Tanwar et al., 2002). YKL40 is reported to predict radioresist-
ance in human tumors (Pelloski et al., 2005) and to promotethe centroids. B: Different sets of normal cells or tissues resemble each of the three centroids. Samples are as follows: fetal brain, adult brain (brain), two neural
stem cell lines derived from fetal tissue (NSC1, NSC2), Jurkat, hematopoietic stem cells (HSC), smooth muscle (SmoMusc), endothelial cells (endothel), syno-
vium (synov), and bone. Neural stem cell lines treated by exposure to and withdrawal from the growth factor BDNF are designated NSC1* and NSC2*.
C: Twenty-six pairs of matched primary and recurrent astrocytomas (red, grade IV; blue, grade III) are represented. Each pair of matched specimens is con-
nected by an arrow that is solid and bold for instances of signature class shift.
D: Genes upregulated in cases that shift into Mes subclass upon recurrence. FC, fold change.
E: IHC of YKL40 and OLIG2 in matched primary and recurrent tumors from a case that undergoes a shift from PN to Mes phenotype.161
A R T I C L EFigure 3. Tumor subclasses are distinguished by markers of proliferation, angiogenesis, and neurogenesis
Aand B:Open circles, brain; green circles or bars, PN; blue triangles or bars, Prolif; red squares or bars, Mes. Horizontal bars denote mean values.A: Prolif HGGs
are enriched for expression of PCNA and TOP2A; p < 13 1026 for comparisons with all other groups. B:Mes HGGs are distinguished by increased expression of
PECAM, VEGF, VEGFR1, and VEGFR2; p < 0.05 for comparisons with all other groups.
C: Among WHO grade IV tumors, Prolif tumors show higher tumor cell Ki-67 labeling index than either PN or Mes tumors (**p < 0.002, both comparisons), while
Mes tumors show increased Ki-67 labeling index in the vascular cells compared to PN or Prolif tumors (*p < 0.01 both comparisons). Error bars denote standard
error of the mean.162 CANCER CELL MARCH 2006
A R T I C L Eclonogenic survival following radiation in vitro (Nigro et al.,
2005), findings consistent with a relative increase in expression
upon tumor recurrence after treatment. No genes were found to
be significantly downregulated in cases that shift intoMes class.
Immunohistochemistry (IHC) on tissue from cases that shifted
from PN to Mes upon recurrence suggested frequent loss of
OLIG2 expression and upregulation of YKL40 in the recurrent
sample. In the example shown in Figure 2E, a PN tumor showing
prominent nuclear expression of OLIG2, a PN marker associ-
ated with low-grade lesions (Ligon et al., 2004), exhibited rela-
tive loss of OLIG2 expression at recurrence. Normal brain ex-
hibited only low-level staining in oligodendroglia, indicating
that upregulation of this marker by PN tumors in array data is
not a manifestation of normal brain contamination during tissue
processing. Conversely, while YKL40, a Mes marker, was ex-
pressed only in rare tumor cells in the primary sample, abundant
expression is seen in the recurrence. Such changes in relative
expression of YKL40 were seen in all tumors examined with
a Mes shift at recurrence.
Poor prognosis tumor subtypes are distinguished
by markers of proliferation or angiogenesis
To determinewhether proliferation or angiogenesismay contrib-
ute to differences in aggressiveness of tumor subclasses, we
examined expression of relevant markers in a set of AA/GBMs
that included 12 representative cases of each subclass. Prolifer-
ating cell nuclear antigen (PCNA) and topoisomerase II a
(TOP2A), markers of proliferation, were overexpressed in Prolif
as compared to PN orMes tumors (Figure 3A).Mes tumors dis-
played overexpression of angiogenesis markers, including
VEGF, flt1/VEGFR1, kdr/VEGFR2, and the endothelial marker
PECAM1 (Figure 3B).
To directly address whether GBMmolecular subtypes differ in
the extent of tumor cell proliferation and/or microvascular prolif-
eration (MVP), IHC with Ki-67 was employed on a set of clear
examples of each molecular subtype of WHO grade IV astrocy-
toma (Table S1; n = 8 PN, 11 Prolif, 11Mes). The mean percent
of Ki-67-positive tumor cells was higher in Prolif tumors com-
pared to the PN orMes tumors (Figure 3C). In contrast, Ki-67 in-
dex in the vasculature was higher in Mes tumors compared to
either remaining subtype (Figure 3C). We also noted frequent
mitotic figures in the vascular cells of Mes tumors (Figure 3D)
and their absence in nearly all Prolif or PN tumors.
Tumors of poor prognosis subtypes express markers
of neural stem cell and/or transit-amplifying cells,
while tumors of the PN subclass express markers
of neuroblasts or neurons
Some of the PN markers in the signature gene set, such as
NCAM, GABBR1 and SNAP91, are associated with neurons.
In light of recent findings that tumorigenic cells of GBM express
the neural stem cell marker CD133 (Singh et al., 2004), we
sought to compare the expression of markers for neural stem
cells versus markers of committed neuronal lineage (FiguresCANCER CELL MARCH 20063E–3G). We selected markers associated with adult forebrain
neurogenesis (Abrous et al., 2005; Anton et al., 2004; Nakano
et al., 2005; Shi et al., 2004). For five out of six markers of neural
stem cells or multipotent transit-amplifying cells, one or both of
the poor prognosis tumor subclasses showed elevated expres-
sion compared to PN tumors (Figure 3E). Such differences were
seen with VIM, nestin (NES), TLX, CD133, and MELK. While
DLX2, a marker of transit-amplifying cells, did not show statisti-
cally significant differences between tumor groups, some Prolif
tumors showed strong expression of this gene. In contrast to
stem cell markers, markers of neuroblasts or developing neu-
rons were overexpressed in PN tumors as compared to Prolif
and/or Mes tumors (Figure 3F). These markers include OLIG2,
MAP2, DCX, ENC1 (NeuN), ERBB4, and GAD2. Expression of
neuronal markers in PN tumors was not accounted for by con-
tamination of tumor specimens with normal brain, as expression
levels of OLIG2, DCX, NeuN, and GAD2 were elevated in tumors
as compared to normal brain specimens (data not shown; p <
0.005 for all Student’s t test comparisons of tumor versus nor-
mal). GFAP, a marker of both neural stem cells and astrocytes,
was more strongly expressed in tumors of both Mes and PN
subclasses as compared to Prolif tumors (Figure 3G).
Losses on chr 10 and gains on chr 7 are associated
with Prolif and Mes tumor subtypes
Of the cases examined by expression profiling, DNA from 96
specimens of AA and GBM was available for analysis by array
comparative genomic hybridization (CGH). Tumors were scored
for relative copy number changes on chrs 1, 7, 10, and 19. The
majority of samples demonstrated gains on chr 7 and losses on
chr 10, and there were striking differences between tumor sub-
classes in the frequency of such changes (Figure 4A; p < 1 3
10210 for chr 10, p < 1 3 1026 for chr 7, Fisher’s exact test).
While the majority of Prolif and Mes tumors had losses on chr
10 that span 10q23.3 (78% and 84%, respectively) and gains
on chr 7 (74%and 82%, respectively), aminority of thePN tumor
subclass showed losses on chr 10 or gains on chr 7 (20% and
23%, respectively). For Mes tumors, most cases had relative
losses at all loci on chr 10 and gains of all loci on chr 7. In con-
trast, Prolif tumors had more heterogeneous patterns of losses
on chr 10. A significant association was also seen between tu-
mor signature and relative copy number changes on chr 19q
(Figure 4A; p < 0.005), but not on chr 1p or chr 1q (p > 0.05).
Given the association between relative genomic copy number
changes and tumor subtypes, we sought to determine whether
the genes that define each tumor subtype show differences in
the distribution of chromosomal locations. Chi-square analysis
on the extended lists of tumor subclass markers (Table S3) re-
vealed that, for each of the three lists, the observed frequencies
of chr locations differed significantly from that expected by the
frequencies of locations for all probe sets on the expression ar-
rays (Figure 4B and Figure S2, p < 13 10214 forPN, p < 0.001 for
Prolif, p < 0.0005 for Mes). PN and Mes marker lists overrepre-
sent markers on chrs 10 and 19, respectively (p < 0.05 for bothD: Mes tumors were characterized by the frequent occurrence of mitotic figures (arrows) in the vascular component.
E and F: Relative to PN tumors, Prolif and/or Mes tumors show stronger expression of the neural stem and transit-amplifying markers VIM, NES, TLX, CD133, MELK,
and DLX2 (E) and weaker expression of the neuroblast and neuronal markers OLIG2, MAP2, DCX, NeuN, ERBB4, and GAD2 (F). Asterisk indicates difference
from PN (p < 0.05).
G: GFAP expression is decreased in Prolif tumors relative to either PN or MES tumors.163
A R T I C L EFigure 4. Copy number changes on chrs 7, 10,
and 19 differ in tumor subclasses and are re-
flected in expression signatures
A: Frequencies of copy number changes of chrs
10, 7, and 19q as a function of tumor signature
subclass. For chr 10, tumors are reported as ex-
hibiting either no losses, losses confined to 10q
that include the PTEN locus, or losses of essentially
all loci. For chr 7, cases are scored as no gains,
gains of any portion of chr 7, or gain of all loci.
For chr 19q, cases are scored as gains or losses
if over one-half of the loci show copy number
changes.
B: Number of probes sets in PN, Prolif, or Mes tu-
mor marker lists (as labeled) compared to all
U133A and U133B probe sets plotted as a func-
tion of chromosome location.comparisons after Bonferroni correction for 72 comparisons).
These findings corroborate the differences between tumor sub-
types in relative DNA copy number changes on chrs 10 and 19q.
Markers of Notch and Akt pathways are differentially
expressed in tumor subclasses with good versus
poor prognosis
Consistent with the association of chr 10 loss and tumor sub-
class, examination of array CGH data for the PTEN locus con-
firmed that a high percentage of Prolif andMes cases displayed
relative losses of this locus. A negative association was seen
between CGH ratios for the PTEN locus and similarity to the
PN centroid (Figure 5A). Most cases of gains or amplifications
of the EGFR locus were tumors of either Prolif or Mes sub-
classes, and a negative correlation was seen between EGFR
copy number gains and similarity to the PN centroid (Figure 5B).
No obvious amplifications or deletions were seen at loci corre-
sponding to AKT1, AKT2, or AKT3, nor of catalytic subunits of
PI3K (data not shown). A small number of samples demon-
strated relative copy number gain for PIK3R3, a regulatory sub-
unit of PI3K, and CGH ratios for this locus were positively corre-
lated with similarity to the Prolif signature (Figure 5C).
Since our results suggested strong relationships between Akt
pathway activation and tumor subtypes, we compared PTEN
mRNA expression and phospho-Akt (p-Akt) IHC in tumor sub-
types. We found that Prolif andMes tumors expressed approx-
imately 2-fold lower PTENmRNA and stronger p-Akt (ser473) as
compared to PN tumors (Figures 5D and 5I). The results were
highly significant (p < 5 3 1025 for PTEN mRNA, p < 5 3 1028
for p-Akt IHC for Student’s t tests of PN versus other). The
PTEN results were validated in a second independent sample
set (Tables S1 and S5).164When we examined the complete list of PN tumor markers in
the MDA sample set (Table S3), probe sets corresponding to the
Notch pathway elements DLL3, DLL1, HEY2, and ASCL1 met
our criteria for markers of PN tumors (Figures 5E–5H). These
genes were confirmed to be overexpressed in PN tumors of
the validation data set (Table S5). Each of these Notch pathway
elements has been implicated in forebrain neurogenesis (Cam-
pos et al., 2001; Casarosa et al., 1999; Sakamoto et al., 2003),
and ASCL1 has recently been linked to specification of both
neurons and oligodendroglia in the adult forebrain (Parras
et al., 2004). Elements of the Notch pathway for which microar-
ray data did not show upregulation in PN tumors include
NOTCH1–NOTCH4, JAG1 and JAG2, HES1, HES2, HES4,
HES6, and HES7 (data not shown). HEY1 showed a small but
significant upregulation in MDA PN tumors (1.4 fold change,
p = 5 3 1025).
To examine direct evidence for Notch signaling activation, we
utilized a blinded assessment of nuclear Notch immunoreactiv-
ity in all MDA cases with available paraffin-embedded sections.
Positive cases showed a weak but discernible ‘‘blush’’ in the nu-
cleus, as compared to negative cases, which showed a com-
plete absence of nuclear staining. Figure 5J displays frequen-
cies of each tumor subtype rated 0, 1, or 2 for Notch nuclear
staining. Ratings ofPN samples were demonstrated to be signif-
icantly higher than those of either Prolif (p < 0.005, Student’s
t test) or Mes (p < 0.001, Student’s t test) subclasses.
A two-gene model of DLL3 and PTEN expression
predicts survival of high-grade astrocytoma
Since our data suggested a role for Notch and Akt pathways in
tumor aggressiveness, we sought evidence for a direct associ-
ation between expression of pathway markers and survival.CANCER CELL MARCH 2006
A R T I C L EFigure 5. Prolif and Mes tumors display differen-
tial activation of Akt and Notch pathways
PN, Prolif, and Mes tumors are denoted by green
circles, blue triangles, and red squares, respec-
tively.
A–C: For each sample, the x axis displays the
CGH log2 ratio for the locus sampled, while the
y axis indicates similarity to either the PN or Prolif
centroid, as indicated. r values indicate Pearson
and Spearman correlation coefficients between
CGH ratios and centroid similarities. PTEN loss (A)
and EGFR amplification (B) are negatively asso-
ciated with the PN signature, while gain of the
PIK3R3 locus (C) is positively associated with the
Prolif signature.
D: Normalized PTEN mRNA levels are lower in
poor prognosis tumor subtypes compared to
the PN tumor subclass. Horizontal lines denote
group means.
E–H: PN tumors show strong overexpression of the
Notch pathway elements DLL3, DLL1, HEY2, and
ASCL1.
I and J: Tumor subclasses differ in staining for
p-Akt and nuclear Notch. For each tumor sub-
type, the fraction of samples rated as 0, 1, or 2
for p-Akt (I) or nuclear Notch (J) immunostaining
is depicted. PN, Prolif, and Mes subtypes are indi-
cated by green, blue, and red bars, respectively.For this analysis, we evaluated PTENmRNA by qPCR and DLL3
mRNA by microarray data from all samples in the MDA survival
set where sufficient mRNA was available (n = 65). A Cox model
revealed that levels of PTEN and DLL3 mRNA and their statisti-
cal interaction were all associatedwith survival in high-grade as-
trocytoma and combined to form a highly significant predictive
model (likelihood ratio test of 21.6 compared to a chi-square ref-
erence distribution with 3 degrees of freedom; p < 0.0001). The
predicted survival functions depicted in Figure 6A demonstrate
that low expression of PTEN mRNA was associated with poor
survival regardless of the level of DLL3 expression. For the cir-
cumstance of high PTEN expression, estimated survival varied
as a function of DLL3 such that high levels of both PTEN andCANCER CELL MARCH 2006DLL3 mRNAs were associated with the best outcome. We
next fitted the same model with a smaller (n = 34) independent
set of UCSF grade III and IV astrocytomas and found that the re-
sulting predicted survival curves were strikingly similar to those
obtained from the MDA sample set (Figure 6B).
Expression signatures of GBM cell lines predict
EGF/FGF-independent neurosphere growth
To examine the biological significance of the molecular tumor
signatures, we examined the ability of GBM cell lines with vary-
ing signatures to grow neurospheres. We profiled 16 GBM cell
lines for mRNA expression and investigated their ability to gen-
erate neurospheres in the presence or absence of EGF + FGF.165
A R T I C L EFigure 6. Expression of PTEN and DLL3 predicts survival of high-grade astrocytoma
Aand B: Estimated survival functions of two sample populations (n = 76 forA; n = 34 for B) modeled for the instance of PTEN expression at the 20th (left) and 80th
percentile (%-ile, right). Blue and red lines show estimated survival for samples with DLL3 expression at the 20th and 80th %-ile of expression, respectively.All 16 lines were negatively correlated with respect to the PN
centroid but showed a wide range of similarities to the Mes
and Prolif centroids. While 15 of the 16 cell lines generated neu-
rospheres that could be propagated in EGF + FGF, their ability to
generate neurospheres that grow in the absence of EGF + FGF
varied (Figure 7A) and was correlated with the expression signa-
ture of the parental cell line (Figure 7B). Most strikingly, we found
that the two cells lines most negatively correlated to the Mes
centroid (G112 and G122) generated neurospheres that grew
rapidly in the absence of EGF + FGF,while cell lineswith a strong
positive correlation to the Mes centroid failed to generate neu-
rospheres that could be readily propagated in the absence of
EGF + FGF (Figure 7B).
Summary of findings
A summary of major findings, including the parallels between tu-
mor subtypes and stages in forebrain neural development, is
displayed in Figures 8A and 8B.166Discussion
At present, gliomas are diagnosed by histopathological criteria,
and known robust prognostic factors for most of these tumors
are limited to tumor grade and patient age. The widespread ac-
ceptance that losses on chrs 1p and 19q are of prognostic value
in oligodendroglioma (Cairncross et al., 1998) has spurred inter-
est in developing molecular markers to predict outcome and
response to treatment across a broader population of gliomas.
While numerous genetic alterations have been described in
GBM (von Deimling et al., 1995; Watanabe et al., 1996), such
markers have proved to be of marginal utility in predicting out-
come or guiding decisions about disease management. Impor-
tantly, recent expression profiling studies have revealed thatmo-
lecular classification of gliomas canbeof prognostic value (Freije
et al., 2004;Nutt et al., 2003). In the current study,we identifymo-
lecular signatures associated with tumor aggressiveness as well
aswith disease progression and relate these signatures to differ-
ences in signaling pathways implicated in gliomagenesis.CANCER CELL MARCH 2006
A R T I C L EFigure 7. Expression signatures of glioma cell
lines predict neurosphere growth
A: Neurosphere cell line cultures (names as indi-
cated) maintained in the presence or absence
of EGF + FGF, showing range of growth (rated
0–4) in the absence of EGF + FGF.
B: Neurosphere growth of 16 cell lines as a func-
tion of correlation of expression signature to the
Mes or Prolif centroids. Spearman r as indicated.Tumor subclasses have prognostic value and delineate
a pattern of disease progression
We report here a previously unreported prognostic classification
scheme for HGG that assigns tumors to subtypes based on sim-
ilarity to defined expression signatures. This classification
scheme offers prognostic value that is independent of tumor
grade and that may be useful for predicting outcome of GBM
cases. Each of the three molecular subtypes of glioma identified
resembles a distinct set of tissues and is enriched for markers of
different aspects of tissue growth. While the current analysis
utilizes a set of 35 signature genes, these molecules are repre-
sentative ofmuch longer lists ofmarkers that identify each tumor
subtype. One HGG subtype, which we term proneural (PN), is
distinguished by markedly better prognosis and expresses
genes associated with normal brain and the process of neuro-
genesis. Two poor prognosis subtypes, characterized by a re-
semblance to either highly proliferative cell lines or tissues of
mesenchymal origin, show activation of gene expression pro-
grams indicative of cell proliferation or angiogenesis, respec-
tively. We speculate that the poor survival associated with the
Prolif andMes tumor types is related to a growth advantage con-
ferred by either a rapid rate of cell division or enhanced survival
of tumor cells afforded by neovascularization. Quantitative as-
sessment of Ki-67 IHC in a set of WHO grade IV astrocytomas
revealed thatProlif tumors exhibit a higher percentage of cycling
tumor cells compared with other subclasses, whileMes tumors
exhibit evidence of increased MVP. Previous studies have sug-
gested the prognostic value of markers of proliferation or angio-
genesis in glioma (Ho et al., 2003; Hsu et al., 1996; Osada et al.,
2004) but have not indicated the existence of distinct GBM sub-
sets that are differentially associated with these processes. Of
note, our Prolif and Mes glioma subtypes are characterized by
expression of portions of a wound-healing signature that has
been associated with poor outcome in several epithelial tumor
types (Chang et al., 2005).
We note that grade III tumors and grade IV tumors lacking ne-
crosis were predominately PN subtype. Importantly, however,CANCER CELL MARCH 2006the PN tumor subtype also includes a set of GBM tumors with
improved outcome that display necrosis and cannot be dis-
tinguished from poor prognosis tumor subtypes by qualitative
histological examination. Thus, our results add to the growing
consensus that molecular categorization may prove to be supe-
rior to histological grading in predicting prognosis.
The tumor subtypes identified in the current study bear re-
semblance to previously reported prognostic subtypes identi-
fied by expression profiling. In particular, three previous studies
report phenotypes that closely resemble the PN and Mes HGG
subtypes that we describe (Freije et al., 2004; Liang et al.,
2005; Nigro et al., 2005). In addition, previous work (Godard
et al., 2003) highlights a cluster of angiogenic genes defining
a tumor subpopulation that appears similar to our Mes tumor
subtype. Our observation of a mutually exclusive pattern of ex-
pression ofPN versusMesmarkers helps explain the consensus
regarding the existence of these two tumor subtypes. Even
within tumor specimens that express both PN andMesmarkers,
the spatial distribution appears to be nonoverlapping. The
strong association between loss of chr 10 and theMes signature
is consistent with previous findings linking chr 10 loss to prog-
nostic tumor subtypes (Nigro et al., 2005) and with the demon-
stration of antiangiogenic actions of chr 10 introduction into
GBM cell lines (Hsu et al., 1996).
The existence of a distinct tumor subtype that is enriched for
proliferative markers has been noted by one previous report
(Freije et al., 2004) but not described in other studies. Our find-
ings indicate that the Prolif signature is less exclusive than PN or
Mes signatures and that the proportion of gliomas that occur
with a Prolif signature varies across sample populations ob-
tained fromdifferent institutions. In support of our categorization
of the Prolif tumor subclass as a distinct molecular subtype of
tumor, we point to the existence in Prolif tumors of a pattern
of genomic alterations that distinguishes this tumor subtype.
Most notably, gains of the PIK3R3 locus on chr 1 appear to be
a feature that is unique to tumors of the Prolif class. The exis-
tence of a genomic alteration unique to tumors bearing the Prolif167
A R T I C L EFigure 8. Summary of tumor subtypes
A: Major features of tumor subtypes.
B: Model depicting parallels between tumor sub-
types and stages in neurogenesis.signature argues in favor of the designation of these tumors as
a distinct subclass and suggests that epidemiological factors
may have influenced the incidence of this subclass in the popu-
lations we investigated.
The strikingmutual exclusivity of thePN andMes tumor signa-
tures suggests the possibility that these tumor subtypes reflect
distinct disease entities, perhaps arising from different cell types
of origin. By studyingmatched pairs of primary and recurrent tu-
mors from the same patients, however, we observe that some
tumors that originally arise as PN or Prolif subtype recur with
a Mes signature. Focal expression of YKL40, a marker of the
Mes phenotype, is seen in primary tumors, including those168that shift to Mes class upon recurrence. Notably, no instances
are seen of tumors gaining appreciable PN character between
initial presentation and recurrence. Taken together with the abil-
ity of neural stem cell lines to shift from PN toMes signature, the
ability of tumors to change subclass suggests that the tumor
subtypes may represent alternate differentiation states of dis-
ease. We cannot, however, rule out the possibility that some
apparent shifts may reflect tumor heterogeneity rather than tem-
poral changes in tumor character. In addition, our experimental
design does not allow us to distinguish between alterations in
gene expression that reflect disease progression from those
which are elicited by treatment. Nevertheless, our finding ofCANCER CELL MARCH 2006
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cells can acquire the Mes phenotype through accumulation of
genetic or epigenetic abnormalities. The older age of patients
with Mes subtype tumors is consistent with this hypothesis.
While we have no direct evidence for molecular events that
underlie the apparent shift in tumor cell signature, the strong
correlation between losses of chr 10 and the Mes signature
may offer an important insight into the biology of disease pro-
gression. Regardless of underlying mechanism, shifts toward
the Mes phenotype appear to be a common pattern of disease
progression and are reminiscent of epithelial-to-mesenchymal
transitions that are associated with increased malignant behav-
ior of epithelial tumor types.
Markers in Notch and Akt pathways predict
glioma aggressiveness
Our findings demonstrate evidence at genomic, mRNA, and
protein levels for activating alterations of Akt signaling in tumors
of poor prognosis subtypes. A wealth of previous data support
a role for Akt signaling in promoting the formation and growth
of high-grade glial malignancies (Knobbe et al., 2002; Sonoda
et al., 2001). A series of elegant studies in genetically engineered
mouse models has convincingly demonstrated a role for Akt in
promoting formation and growth of glial malignancies (Holland
et al., 2000; Rajasekhar et al., 2003; Uhrbom et al., 2002; Xiao
et al., 2005). In human tumors, both EGFR amplification and
PTEN deletion are well-known alterations that activate Akt and
are specifically associated with the distinction between GBM
versus lower-grade lesions (Stiles et al., 2002). More recently,
bothmutations in PIK3CA and balanced copy number increases
in PIK3CA and PIK3CD have been described in AA and GBM
(Broderick et al., 2004; Mizoguchi et al., 2004; Samuels et al.,
2004). While the prognostic value of EGFR amplification or ge-
netic changes in PI3K subunits is not clear, several studies
have shown that losses on chr 10, loss of the PTEN locus, or en-
hanced PI3K signaling are all associated with poor outcome in
GBM (Chakravarti et al., 2004; Lin et al., 1998; Schmidt et al.,
2002; Tada et al., 2001). Activation of PI3K/Akt signaling is im-
plicated in several biological processes that confer a growth
advantage, including proliferation, survival, and angiogenesis
(Abe et al., 2003; Pore et al., 2003; Su et al., 2003). Thus, we
speculate that the poor outcome of Prolif and Mes subtype tu-
mors may result, in part, from actions of PI3K/Akt signaling to
promote more aggressive growth patterns characterized by
high rate of proliferation or neoangiogenesis, respectively. Cur-
rent findings do not lend a clear hypothesis to explain the diver-
gence between the proliferative versus angiogenic manifesta-
tions of Akt signaling in the two poor prognosis subtypes, but
one possibility is that more frequent loss of loci on chr 10p or
gains on chrs 7 and 19q in Mes tumors may contribute to this
distinction. The high frequency of Mes markers encoded for
on chr 19 is interesting in this regard.
Activation of NOTCH1 signaling has been recently linked to
several malignancies, including glioma (Fan et al., 2004; Purow
et al., 2005; Radtke and Clevers, 2005; Weng et al., 2004). Our
observations demonstrate prognostic value of Notch pathway
markers in HGGs. Specifically, NOTCH1 nuclear staining and
mRNA for several Notch pathway elements are enriched in the
better outcomePN tumor subtype as compared to poor progno-
sis subtypes. Further, we find in two independent sample pop-
ulations that expression of mRNA for DLL3 is correlated withCANCER CELL MARCH 2006longer survival, particularly in cases where PTEN expression is
high. While several interpretations are possible, one interesting
possibility is that in the presence of intact PTEN, inhibitory activ-
ity of DLL3 on Notch signaling (Ladi et al., 2005) may limit tumor
growth by promoting a more differentiated phenotype. Regard-
less of the precise role of Notch signaling, the prognostic value
of our two-gene PTEN andDLL3Coxmodel clearly suggests Akt
and Notch signaling as major determinants of tumor growth.
Parallels between regulation of glioma growth
and forebrain neurogenesis
The current investigation links prognostic tumor subtypes to
differences in relative expression of neural stem cell versus
neuroblast markers as well as to differences in Akt and Notch
signaling elements. One model for human gliomas is that all mo-
lecularly defined subtypes arise from similar cell type(s) of origin,
but some tumors are maintained in more undifferentiated neural
stem cell-like (Mes) or transit-amplifying-like (Prolif) phenotypes,
while others (PN) adopt a phenotype closer to that of neuro-
blasts or immature neurons. This model, supported by animal
studies (Bachoo et al., 2002; Fomchenko and Holland, 2005),
suggests that HGGs may arise from cells at multiple stages of
differentiation from stem cell to neuron or glia, and that pheno-
typic variations among HGGs are determined in large part by
molecular alterations in signaling pathways rather than by differ-
ences in cell type of origin. In light of the critical roles that PTEN
and Notch exert during forebrain neurogenesis to maintain neu-
ral stem cells or progenitors in a proliferating undifferentiated
state (Groszer et al., 2001; Sakamoto et al., 2003; Yoon and
Gaiano, 2005), our findings suggest that aggressiveness of gli-
oma growthmay be largely governed by processes that regulate
cell fate choices during neurogenesis.
The phenotype of the tumor subtypes described in this study
parallels stages in neurogenesis in the adult forebrain (Figure 8).
Similar to committed neuronal precursors, tumors of the PN
subtype appear to have a low rate of proliferation and express
markers seen on neuroblasts and immature neurons. In con-
trast, Mes and Prolif subtype tumors lack neuronal lineage
markers but recapitulate aspects of neural stem cells and/or
transit-amplifying cells. The parallel between the apparently
rapid rate of proliferation of Prolif tumors and the transit-ampli-
fying cells is readily apparent. In addition, we find that tumors of
the Prolif subtype are characterized by robust expression of
MELK, a marker of rapidly proliferating multipotential precursor
cells in the rodent forebrain (Nakano et al., 2005). Further, the
EGFR amplifications in tumors of both Prolif and Mes sub-
classes parallel the responsiveness of both neural stem cells
and transit-amplifying cells to EGF (Doetsch et al., 2002). The
expression of smooth muscle, endothelial cell, and cartilage
markers by Mes tumors is reminiscent of the reported multipo-
tentiality of neural stem cells from adult forebrain (Bani-Yaghoub
et al., 2004; Rietze et al., 2001; Sieber-Blum, 2003; Wurmser
et al., 2004). One caveat in interpretation, however, pertains to
the possibility that tumor expression profiles may be con-
founded by recruitment of stem cell-like populations to the
tumor mass.
Intriguingly, the parallels between the Mes tumor phenotype
and neural stem cells include a recapitulation of the close asso-
ciation seen between neural stem cells and endothelial cells. In
contrast to other tumor subtypes,Mes tumors display robust ex-
pression of VEGF, its receptors, and markers of endothelial169
A R T I C L Ecells. Recent findings indicate that VEGF promotes proliferation
and survival of adult forebrain neural stem cells and demon-
strate that secreted factors from endothelial cells also promote
neural stem cell proliferation (Cao et al., 2004; Fabel et al., 2003;
Jin et al., 2002; Maurer et al., 2003; Schanzer et al., 2004; Shen
et al., 2004; Yasuhara et al., 2004; Zhu et al., 2003). It is interest-
ing to speculate that the growth of tumor cells ofMes phenotype
tumors may be supported by the actions of increased levels of
VEGF and/or endothelial-derived factors. In this regard, thera-
pies that target VEGF or its receptors might prove beneficial in
not only targeting neovasculature, but also directly inhibiting
growth of tumor cells that manifest a neural stem cell-like biol-
ogy. Targeted inactivation of VEGF in the neural tube has been
recently demonstrated to produce both vascular defects and
a profound degree of neuronal apoptosis in the murine forebrain
(Raab et al., 2004).
Our in vitro finding that neurosphere growth of GBM cell lines
correlates with expression signature suggests that the stem
cell-like behavior of primary tumors might also be predicted
from signature subclass. These findings point to the possibility
that expression signatures may predict responses of both cell
lines and primary tumors to targeted therapies.
Therapeutic implications
The present findings offer several implications for the develop-
ment of effective therapies for glioma. First, the current investi-
gation adds to the growing consensus that optimal treatment of
glial malignancies may rely on regimens targeted at distinct mo-
lecular categories of tumor (Mischel et al., 2003; Newton, 2004;
Rao et al., 2003). Second, our findings support the value of
targeting both Akt and Notch pathways in the potential devel-
opment of novel therapeutic regimens for HGG. Third, the sug-
gestion that tumor recurrence after standard therapies may be
accompanied by a phenotypic shift into a mesenchymal, angio-
genic state underscores the value of targeting this aggressive
phenotypic state even in tumors with a less aggressive pheno-
type. Finally, correlations between stem cell biology and glioma
aggressiveness suggest that greater understanding of forebrain
neurogenesis may lead to novel insights for therapeutic inter-
vention in glial malignancies.
Experimental procedures
Tumor samples and patient characteristics
A summary of all glioma cases studied is included in Table S1. For survival
analysis, two expression profiling data sets were generated using frozen tis-
sue samples from 76 MDA cases and RNA from 39 UCSF cases (Nigro et al.,
2005). Cases analyzed met the following criteria. Fresh-frozen samples were
obtained at the time of initial surgical resection from patients (>21 years of
age) without prior therapy. Clinical follow-up information was available for
a period of at least 2 years postsurgery or until death. Institutional Review
Board/Human Subjects approval was obtained for these retrospective labo-
ratory studies at UCSF and MDA. Cases were graded according to WHO cri-
teria (Kleihues and Cavenee, 2000; see Table S2), and sections from frozen
tissues were examined by a neuropathologist (K.A.) to ensure that R90%
of the sample represented tumor. Unusual histological variants were ex-
cluded. In addition, a third previously published data set study (Freije et al.,
2004) was utilized for validation of the prognostic value of our classification
scheme. For analysis of this data set (Figure S1), we utilized data from all
cases that met our criteria for patient age and microarray quality control pa-
rameters, including cases of oligodendroglial or mixedmorphology aswell as
cases with survival times censored at less than 2 years.
Normal adult brain tissue consists of autopsy specimens of cerebral cortex
from donors with no history of brain tumor or neurological disorders and was170obtained from the National Neurological Research Brain Bank (Los Angeles,
CA). Description of samples analyzed in Figure 2B, some of which were pro-
filed at GeneLogic Inc (Gaithersburg, MD), is included in Table S4.
Gene expression profiling, CGH, and qPCR
For glioma and brain specimens not included in previous publications (Freije
et al., 2004; Nigro et al., 2005), total cellular RNA was extracted using Qia-
gen’s RNA isolation kit according to the manufacturer’s protocol. Genomic
DNA contamination was removed through an on-column DNase digestion
step. Affymetrix U133A and U133B chips were employed for expression pro-
filing according to a previously published technique (Tumor Analysis Best
Practices Working Group, 2004). Quality control parameters were as de-
scribed in this publication with the exception that 30/50 ratios of >3 for actin
were allowed if the 30/50 ratio for GAPDHwas <3. qPCRwas performed in du-
plicate for each sample on the ABI Prism7700 Sequence Detector (Applied
Biosystems, Foster City, CA) with TaqMan PCR Core reagents (Applied Bio-
systems, Foster City, CA). Twenty-five nanograms of total RNA was used in
each 50 ml reaction. RAB14 was used for normalization, as it exhibits very lit-
tle variation in expression across a large number of samples. All primer pairs
were designed to generate amplicons of 67–79 bp. DNA extraction and array
CGH were performed as previously described (Misra et al., 2005). Of the 96
samples analyzed via CGH, data for 43 samples came from a previously pub-
lished study (Nigro et al., 2005). The microarray data have been submitted to
Gene Expression Omnibus (GEO), and the accession number for the data se-
ries is GSE4271.
Analysis of microarray data
Signal intensity values from Microarray Analysis Suite version 5 were utilized
with a scaling factor of 500 for all analysis of microarray data. K-means clus-
tering and agglomerative clustering were performed with the use of Spotfire
Decision Site software version 7.3 using Pearson correlation as the similarity
measure. For each gene, data were normalized into Z scores prior to cluster-
ing. The 35 signature genes used for tumor classification represent the most
robust markers for each of three tumor subsets in the MDA survival sample
set. Markers of each subset were identified as follows. Each of the 76 sam-
ples was assigned to one of three groups by k-means clustering using
expression of the 108 genes most strongly correlated with survival. Using
a p value cutoff of 13 1024, Student’s t tests were utilized to identify all genes
whose expression differed between samples in each subclass compared to
tumors of other subclasses. Genes meeting this statistical cutoff and show-
ing at least 2-fold overexpression are included in the extended list of markers
for each tumor subset (Table S3). Probe sets used as signature genes for
each tumor subtype were determined as follows. For each Student’s t test
comparison, we rank-ordered the 500 probe sets with the smallest p values
by fold change and selected those corresponding to identified full-length
sequences that showed the greatest fold change and that met a minimum
expression cutoff (mean intensity of 400 within group of interest). Empirical
determinations using k-means clustering revealed that stable sample clus-
ters resulted when clustering was performed using 30 to 60 probe sets, pro-
vided that the gene list for clustering was balanced to include fewer Prolif
markers. The final 35 signature genes contained 15 PN, 15Mes, and 5 Prolif
markers. Similarity scores toPN,Prolif, andMes centroids represent Pearson
correlation coefficients to each of the centroids generated in k-means clus-
tering of the 76 MDA survival samples. For statistical comparisons of data
presented in Figures 3 and 5, data (or log-transformed microarray data)
were analyzed via ANOVA and post hoc Student’s t tests with Bonferroni cor-
rection. Log-transformed expression data were also utilized for the statistical
analysis performed for Figure 6.
In situ hybridization and IHC
33P-UTP-labeled antisense riboprobes were transcribed using in vitro
transcription (Promega, Madison, WI) and hybridized to paraffin-embedded
human glioma tissue microarrays utilizing a previously described method
(Phillips et al., 1990). Images depicted in Figure 1 are from a tissuemicroarray
obtained from Petagen, Inc. The probe to BCAN represents a 668 bp frag-
ment (939 to 1606), and that for YKL40 represents a 1158 bp fragment
(121 to 1278).
IHC was performed on paraffin-embedded sections as previously de-
scribed (Simmons et al., 2001). Primary antibodies were anti-p-Akt (ser473)
from Cell Signaling Technology (Beverly, MA), anti-Ki-67 (MIB-1) from DakoCANCER CELL MARCH 2006
A R T I C L E(Carpinteria, CA), anti-Olig2 from Immuno-Biological Laboratories (Fujioka,
Japan), and anti-Notch from Santa Cruz Biotechnology (Santa Cruz, CA).
Ratings were performed by a neuropathologist (K.A.) blinded to the signature
group of the specimens. Ki-67 labeling index in the tumor cells was per-
formed by identifying the highest area of staining on low power, then counting
1000 cells in that region to determine the percent of labeled cells. Prolifera-
tion in vascular cells was determined by identifying a positively stained vas-
cular cell (if present) and then counting after randomly choosing additional
areas until 100 vascular cells were counted.
In vitro studies
Previously described GBM cell lines were utilized for in vitro studies (Hart-
mann et al., 1999). For neurosphere cultures, cells positively sorted with
CD133 beads were maintained in culture as described for primary GBM
specimens (Singh et al., 2004). All neurosphere cultures were maintained in
neurobasal medium (Invitrogen) with N2 supplement (Invitrogen) and NSF1
(Cambrex). When present, EGF and FGF were added at a concentration of
20 ng/ml. Each cell line is rated for neurosphere growth in the absence of
EGF + FGF by an observer blinded to themolecular signature of the cell lines.
Rating scale was as follows: 0 = no viable neurospheres; 1 = slowly expand-
ing neurospheres; 2 =moderate growth rate; 3 =moderate to fast growth, but
slower than that seen with EGF + FGF; 4 = rapid growth that is not acceler-
ated by EGF + FGF.
Supplemental data
The Supplemental Data include two supplemental figures and six supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/3/157/DC1/.
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